Biotech Active Movers: Agenus Inc. (NASDAQ:AGEN), Arena Pharmaceuticals (NASDAQ:ARNA), Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN), Novavax (NASDAQ:NVAX)

On 9 January Agenus Inc. (NASDAQ:AGEN) announced a global license, development and commercialization agreement with Incyte Corp. Incyte will make upfront payments to Agenus totaling $25 million and will also invest $35 million in the company, through the purchase of newly issued shares of Agenus. On Friday shares of Agenus Inc. (NASDAQ:AGEN) closed at $5.29. Company’s sales growth for last 5 years was 2.10%

On 7 January Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced top-line results from a Phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in last trading activity decreased -5.73% to close at $5.43. Company weekly performance is 51.25% while its quarterly performance stands at 45.19%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is -31.87% away from its 52 week high.

On 6 January Gilead Sciences Inc. (NASDAQ:GILD) announced that it has agreed to acquire Phenex’s Farnesoid X Receptor program. The development program is focused on the treatment of liver diseases, including nonalcoholic steatohepatitis. On last trading day Gilead Sciences Inc. (NASDAQ:GILD) decreased -0.09% to close at $102.21. Its volatility for the week is 3.00% while volatility for the month is 3.36%. GILD’s sales growth for past 5 years was 16.00% and its EPS growth for past 5 years was 11.90%. Gilead Sciences Inc. (NASDAQ:GILD) monthly performance is -3.49%.

Robert W. Baird downgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from an outperform rating to a neutral rating in a research note released on Friday morning. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has 44.11% insider ownership while its institutional ownership stands at 90.70%. In last trading activity company’s stock closed at $14.56.

Novavax, Inc. (NASDAQ:NVAX) Director, Evans Gary C had unloaded 30,000 shares at $5.77 per share in a transaction on December 12, 2014. The total value of transaction was $173,100. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. On last trading day Novavax, Inc. (NASDAQ:NVAX) moved up 6.05% to close at $6.31. Its volatility for the week is 4.79% while volatility for the month is 4.55%. NVAX’s sales growth for past 5 years was 80.20% and its EPS growth for past 5 years was 9.50%. Novavax, Inc. (NASDAQ:NVAX) monthly performance is 13.69%.

Leave a Reply

Your email address will not be published. Required fields are marked *